logo
  

Stock Alert: Corvus Pharma Surges 111%; Study Initiated For COVID-19 Treatment

Shares of Corvus Pharmaceuticals, Inc. (CRVS) more than doubled on Tuesday morning after the clinical stage biopharmaceutical company said it commenced a Phase 1 clinical study testing a novel treatment for COVID-19.

CRVS is currently trading at $5.80, up $3.06 or 111.68%, on the Nasdaq.

Corvus announced that it has initiated an early-state study to investigate a novel immunotherapy approach for patients with COVID-19. The study is expected to enroll up to 30 patients at several sites in the United States.

The enrollment follows the FDA's review and acceptance of the company's investigational new drug application for the COVID-19 study.

Corvus is studying an agonistic (immunostimulatory) humanized monoclonal antibody, designated as CPI-006, which has demonstrated a potential new approach to immunotherapy of infectious diseases and cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Nestle Purina PetCare Co. has recalled a limited amount of certain prescription wet dog food citing labeling error, the U.S. Food and Drug Administration said. The recall involves Purina Pro Plan Veterinary Diets EN Gastroenteric Low Fat or PPVD EN Low Fat wet dog food that comes in 13.4 oz cans. Exportadora Copramar is recalling 1260 cases of James Farm frozen raspberries citing potential to be contaminated with Hepatitis A, the U.S. Food and Drug Administration said. The recall involves James Farm branded frozen raspberries identified by UPC Code: 76069501010 and Lot Code - 22-165. American Honda Motor Co, Inc. has recalled about 2,900 units of 2022 model year Honda TRX90X All-Terrain Vehicles (ATVs) sold in the United States for possible crash and injury hazard, according to a statement issued by the U.S. Consumer Product Safety Commission or CPSC.
Follow RTT